Compare LYFT Inc (LYFT) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LYFT Inc vs Moderna, Inc. — how do they compare? LYFT Inc trades at $15.53 (market cap $5.86B), while Moderna, Inc. trades at $60.04 (market cap $23.60B). The key difference: Moderna, Inc. is far larger — about 4× LYFT Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, LYFT Inc nearer its low. Which is the better fit depends on your goals.
| LYFT | MRNA | |
|---|---|---|
Market Cap | $5.86B | $23.60B |
Sector | Industrials | Health |
52-Week High | $24.57 | $81.80 |
52-Week Low | $12.65 | $22.36 |
Enterprise Value | $5.39B | $19.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lyft trades at $15.39, down 0.84% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company demonstrates strong revenue growth, reaching $6.32B in 2025 with a remarkable net income margin of 43.82%, though recent quarterly EPS results have been inconsistent with two misses and one beat. Analyst consensus leans neutral with 57.6% hold ratings but offers a $17.86 price target suggesting 16% upside potential.
Lyft presents a compelling valuation case with a low P/E of 2.27 and P/S of 0.98, supported by improving cash flow trends and strategic expansions into new markets. However, risks include competitive pressure from Uber, inconsistent earnings performance, and regulatory scrutiny over pricing practices. The upcoming Q2 2026 earnings report on August 6 will be critical for validating the company's growth trajectory.
Moderna (MRNA) trades at $60.47, down 2.18% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported a net loss of -$2.82B in 2025, with revenue declining to $1.92B, though it has beaten EPS estimates in recent quarters. Recent news highlights progress in its cancer pipeline, including a Phase 1 study for mRNA-4200, and an EU contract for its RSV vaccine.
The outlook remains speculative with high execution risk as Moderna transitions beyond COVID-19 vaccines. While pipeline advancements offer long-term potential, persistent losses and negative margins pose significant challenges. Analyst consensus is cautious with a $49 price target, suggesting limited near-term upside amid ongoing fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
